Regeneron Is Betting $2.3 Billion That Peptides Can Crack the Undruggable Problem Antibodies Cannot Touch
Regeneron Is Betting $2.3 Billion That Peptides Can Crack the Undruggable Problem Antibodies Cannot Touch
Regeneron has spent decades perfecting antibodies. Now it is paying $125 million upfront, plus up to $2.2 billion in milestones, for the right to fuse them to a different kind of molecular key.
The biotech announced a collaboration with Parabilis Medicines on Monday to develop Antibody-Helicon Conjugates, a new therapeutic class that pairs Regeneron's VelocImmune antibodies with Parabilis's Helicon peptides. Helicons are stabilized, cell-penetrant alpha-helical peptides designed to engage intracellular protein targets, including surfaces too flat or featureless for traditional small molecules to grip. The goal: reach the roughly 80 percent of proteins that have historically been considered undruggable.
The five initial targets remain undisclosed. Regeneron will handle development, manufacturing, and worldwide commercialization. Parabilis receives tiered royalties on net sales in the low double-digits.
The deal landed the same day Regeneron's shares fell nearly 10 percent, dropping from $698 to $630. That decline had nothing to do with Parabilis. On Friday evening, Regeneron acknowledged the failure of a Phase III trial testing the LAG-3 inhibitor fianlimab combined with its PD-1 drug Libtayo against Merck's Keytruda in first-line melanoma. The combination missed its primary endpoint of progression-free survival. The market's read was blunt: Regeneron's pipeline, outside its eye and inflammation franchises, keeps stumbling.
The Parabilis deal is a different kind of statement. It says Regeneron is willing to pay real money to access a modality it cannot build internally fast enough on its own. That is notable from a company that has historically preferred to invent everything in-house.
Parabilis was founded as FogPharma before rebranding in late 2024. Its Helicon platform uses AI and physics-based modeling to design helical peptides that can penetrate cell membranes and bind to intracellular targets that antibodies cannot reach because they cannot cross the cell membrane. The peptides are stapled and constrained to hold their active shape, which allows them to bind with affinity and selectivity that unmodified short peptides cannot achieve.
The company's CEO is Mathai Mammen, who ran pharmaceutical R&D at Johnson & Johnson before joining FogPharma in 2023. Under his leadership, Parabilis raised $305 million in a Series F financing in January 2026, one of the largest VC rounds in biotech that month, specifically to push its lead candidate zolucatetide through Phase 1/2 and to expand its Helicon pipeline. Beta-catenin is a transcription factor involved in cell adhesion and growth control; mutations in the Wnt/beta-catenin pathway are implicated in a wide range of cancers, including colorectal, hepatocellular, and pancreatic cancers. It has been considered undruggable for decades.
Parabilis is not the only company chasing the undruggable with peptides. Molecular Partners, Peptidream, and several academic spinouts are working on related approaches. But the Regeneron deal is a significant validation: it means the field's largest antibody shop is acknowledging that antibodies alone cannot solve the intracellular target problem.
Antibody-drug conjugates have transformed oncology over the past decade, with 15 approved globally. But traditional ADCs rely on antibodies to ferry cytotoxic payloads into cells, then rely on those payloads to kill the cell from within. The payload is the warhead. In the AHC model Regeneron and Parabilis are pursuing, the Helicon peptide is not a payload — it is a targeted modulator. The Helicon itself is designed to selectively bind and inhibit or degrade a specific protein inside the cell. The antibody's job is to deliver the Helicon precisely to cells of interest, reducing off-target exposure.
This is a harder engineering problem than a traditional ADC. Peptides can be cleared faster than antibodies, and intracellular delivery introduces complexity that simple cell-surface targeting does not. Whether AHCs can achieve the pharmacokinetics and tissue distribution needed for clinical utility remains an open question.
The deal structure — $50 million cash, $75 million equity, with $2.2 billion in milestones tied to development, regulatory, and commercial milestones — reflects both the upside Regeneron sees and the stage-gate caution appropriate for an unproven modality. Five targets at that total value implies roughly $440 million per target if everything makes it to market, which is optimistic but not unreasonable for a platform with broad applicability.
The deeper signal is consolidation. Regeneron has watched its oncology franchise stumble — the LAG-3 failure follows earlier setbacks with other IO agents — while competitors like AstraZeneca and GSK have moved aggressively to acquire or partner platform technologies. The Helicon deal gives Regeneron an option on an entire new therapeutic class at a price that does not move the needle on its balance sheet unless the science fails.
Regeneron's pipeline had 36 investigational medicines in development as of its most recent annual report. Not one of them uses a Helicon. After this deal, five will.
The Parabilis-FogPharma rebranding was accompanied by a platform reveal in late 2024, when the company claimed its AI-physics engine could design Helicons against any target with a known or suspected binding surface — a bold claim that the Regeneron deal has now implicitly stress-tested.
This is the right kind of biotech deal to watch: a large, cash-rich pharma company paying real money for access to a differentiated platform, with enough milestone structure to keep Parabilis accountable. The LAG-3 failure is the more immediate story for Regeneron's investors. The Helicon collaboration is the more interesting story for anyone tracking where the next wave of targeted therapies will come from.
https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-strategic-collaboration-parabilis-medicines
https://www.biopharmadive.com/news/parabilis-financing-zolucatetide-beta-catenin-cancer-drug/809079/
https://www.biospace.com/press-releases/parabilis-medicines-formerly-fogpharma-announces-new-company-name-and-unveils-ai-and-physics-based-discovery-platform